ESTRO Guide 2018

First page Table of contents Previous page 130 Next page Last page

TEACHING LECTURE

Should proton therapy clinical practice move away from a constant RBE of 1.1?

Pre-clinical cancer models

Supportive care in head and neck radiotherapy

Anal cancer: can we individualise treatment?

Oesophagus cancer

08:00 - 08:40

SYMPOSIUM

European Particle Therapy Network (EPTN) EPTN WP1: Clinical trial designs to assess the benefit of protons - EPTN WP2: Dosimetry and quality assurance - EPTN WP4: Imaging - EPTNWP5: Treatment planning systems - EPTN WP6: Radiobiology ESTRO-PROS Is there a reason not to deliver all curative pediatric treatments with brachy or protons? How can brachytherapy compete with other treatment modalities (surgery, external irradiation) or are these techniques complementary? - RTT specific role in brachytherapy for young children - Every single paediatric patient needs to receive proton beam radiotherapy - Not every single paediatric patient needs to receive proton beam therapy COFFEE BREAK JOINT SYMPOSIUM

Mouse cancer clinic; models and modalities for precision imaging and radiotherapy in small animal models State of the art and future develop- ments of small animal imaging and radiotherapy platforms - Mouse Models for cancer PDX; nuts and bolts of preclinical models - Applications of precision radiation in preclinical models; NTCP and TCP

Immunotherapy to complement chemoradiation for head and neck cancer The immune landscape and immunotherapy for head and neck cancer - Role of the immune system in radiation therapy - Designing immuno-radiotherapy trials in head and neck cancer

Novelties in organ-and function sparing treatment in rectal cancer TME, TEM or wait and see? The surgeon’s perspective - Targeted imaging in rectal cancer - The optimal radiotherapy approach for organ preservation - Dose escalation for non-surgical management

Cosmetic appearance after brachytherapy How to measure brachytherapy-related cosmetic changes? - Cosmetic outcome after APBI - Facial growth and developmental outcomes following pediatric head and neck brachytherapy - Late skin sequelae following skin applicator brachytherapy

SUNDAY 22 APRIL 2018 08:45 - 10:00

10:00 - 10:30

PROFFERED PAPERS

10:30 - 11:45

12:00 - 12:10

DONAL HOLLYWOOD AWARD

12:10 - 13:00

HIGHLIGHTS OF PROFFERED PAPERS

13:00 - 14:30

LUNCH AND INDUSTRY SYMPOSIA

SYMPOSIUM

DEBATE

SYMPOSIUM

Immuno-radiotherapy: the crit- ical influence of radiation dose, scheduling and dose per fraction Overviewof themolecular interactions between radiotherapyand the immune systemand immunecheckpoint inhibitors - Pre-clinical data informing dose/dose per fraction and scheduling strategies - Clinical data informing dose/dose per fraction and scheduling strategies - Ongoing and upcoming clinical trials eval- uating different radiotherapy schedules in combination with immunotherapy

New strategies to target hypoxia in combination with radiotherapy Understanding and targeting the underlying drivers of tumour hypoxia - Targeting oxygen consumption - Targeting hypoxia with DNA repair inhibitors

Proton therapy in head and neck cancer: patient selection, validation and future directions Advanced selection procedures for proton therapy in head and neck cancer patients - Model-based clinical validation of proton therapy in head and neck cancer - Carbon ion therapy in adenoid cystic carcinoma

This house believes that 5x5 Gy offers more opportunities for tailor made treatment than con- ventional chemoradiotherapy in rectal cancer patients

Prostate brachytherapy: LDR seeds versus HDR monotherapy Differences in dosimetry, treatment planning and equieffective dose - Long-term results of LDR seed monotherapy in the treatment of prostate cancer - Long-term results of HDR monotherapy in the treatment of prostate cancer - LDR seeds versus single-fraction HDR monotherapy: early results of a randomised phase III clinical trial

14:30 - 15:45

15:45 - 16:15

COFFEE BREAK

SYMPOSIUM

PROFFERED PAPERS

CONFERENCES

Oligometastaic disease Evidence for local treatment in metastatic disease - Planning and delivery strategies for oligometastatic disease - Protons for oligometastases?

16:15 - 17:30

130

17:45 - 18:15

IRIDIUMAWARD LECTURE

Made with FlippingBook Online newsletter